Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • NHS Scotland

    - PMLiVE

    Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

    Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

    - PMLiVE

    Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC

    The rare muscle-wasting disorder affects approximately 2,500 males in the UK at any one time

    - PMLiVE

    Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa

    Rare diseases currently affect around 436,000 people living in Scotland

    - PMLiVE

    Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma

    The fifth-most common cancer in the UK affects more than 1,200 people in Scotland every year

    - PMLiVE

    Celltrion’s RoActemra biosimilar shows promise in phase 3 rheumatoid arthritis study

    The chronic inflammatory disease affects approximately 1% of the population worldwide

    - PMLiVE

    Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

    The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

    - PMLiVE

    Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

    More than 133,520 people in Scotland are affected by the inflammatory condition

    - PMLiVE

    Janssen reveals positive results for nipocalimab in rheumatoid arthritis

    About 13 million people worldwide are affected by the chronic inflammatory disease

    - PMLiVE

    SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease

    XLH is a life-long genetic disease that causes abnormalities in the bones, muscles and joints

    - PMLiVE

    MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

    There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

    - PMLiVE

    Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

    The companies will focus on developing therapies for rheumatoid arthritis and lupus

    - PMLiVE

    AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients

    In Scotland, there are around 44,000 people living with the progressive autoimmune disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links